ArticleEuropean radiology2026
Mammography-based artificial intelligence model for predicting axillary lymph node status after neoadjuvant therapy in breast cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectivesOur objective is to develop a deep learning-based artificial intelligence (AI) model capable of analyzing digital mammography (DM) images to predict axillary lymph node (ALN) status subsequent to neoadjuvant therapy (NAT) in breast cancer patients. MATERIALS AND
methodsWe developed and validated an AI model for predicting post-NAT ALN status using images and clinical data of 956 invasive non-specific breast cancer patients with positive ALN metastasis from three medical centers. During development, four image cropping methods and five backbone networks were compared for classification architecture construction. The AI model was evaluated via internal and external test sets, with performance assessed using the ROC curve and AUC.
resultsExperiments showed that the AI model using "fixed 5 cm" image clipping and Swin Transformer V2 as the backbone feature extraction network for primary image processing achieved the best ALN status prediction performance. Compared with merely inputting the primary lesion, adding the pre-training model and clinical features further improved the prediction performance of the AI model, in the training set (AUC = 0.823, 95% CI: 0.797-0.846, p < 0.001), internal validation set (AUC = 0.774, 95% CI: 0.722-0.818, p < 0.001), internal test set (AUC = 0.778, 95% CI: 0.739-0.813, p = 0.034) and external test set (AUC = 0.756, 95% CI: 0.700-0.805, p = 0.013). After inputting primary and auxiliary region images and clinical features into the AI model, the AUC value was further improved, reaching above 0.8 in all four datasets.
conclusionThis study constructed an AI model based on baseline DM images that demonstrates good performance in predicting ALN status in breast cancer patients after NAT, providing decision support to avoid excessive surgery. KEY POINTS: Question Due to the lack of reliable methods to accurately judge the status of ALNs in breast cancer patients after NAT, some patients are overtreated. Findings The AI model we constructed based on the primary lesion of DM before NAT can predict the status of ALNs accurately after NAT. Clinical relevance The AI model can predict the status of ALNs after NAT, which may help clinical selection of more beneficial treatment modalities.
Indexed as
Identifiers
41999400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.